T Cell Specific Surface Glycoprotein CD28 – Pipeline Review, H2 2019

Global Markets Direct’s, 'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)- Pipeline Review, H2 2019’, provides in depth analysis on T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Hematological Disorders, Musculoskeletal Disorders, Ophthalmology and Toxicology under development targeting T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)

– The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects

– The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Alpine Immune Sciences Inc

Atox Bio Ltd

Avacta Life Sciences Ltd

Bristol-Myers Squibb Co

Five Prime Therapeutics Inc

Imugene Ltd

OSE Immunotherapeutics

Regeneron Pharmaceuticals Inc

TheraMAB LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development

Alpine Immune Sciences Inc

Atox Bio Ltd

Avacta Life Sciences Ltd

Bristol-Myers Squibb Co

Five Prime Therapeutics Inc

Imugene Ltd

OSE Immunotherapeutics

Regeneron Pharmaceuticals Inc

TheraMAB LLC

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles

ALPN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALPN-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target CD28 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FPT-155 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FR-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Target ICOS, CD28 and NCR3LG1 for Colon Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lulizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CD278, CD28 and HER2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Agonize CD28 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-5678 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reltecimod sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAB-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD28 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones

Featured News & Press Releases

Dec 09, 2019: Alpine Immune Sciences presents ALPN-101 phase 1 healthy volunteer study data and details of upcoming phase I/II BALANCE GVHD study at the 61st American Society of Hematology annual meeting

Nov 12, 2019: Alpine Immune Sciences presents new ALPN-101 preclinical data at the 2019 American College of Rheumatology (ACR) Annual Meeting

Nov 09, 2019: Five Prime Therapeutics presents initial safety data from the phase 1 trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting

Nov 08, 2019: Alpine Immune Sciences presents new preclinical data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Nov 06, 2019: Alpine Immune Sciences announces oral presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and Exposition

Oct 30, 2019: Alpine Immune Sciences completes enrollment of phase I study of ALPN-101 and announces third quarter conference call

Oct 02, 2019: Alpine Immune Sciences announces upcoming scientific presentation of ALPN-101 at ACR/ARHP 2019 Annual Meeting

Oct 02, 2019: Alpine Immune Sciences announces upcoming scientific presentation on ALPN-202 at SITC 2019 Annual Meeting

Jun 18, 2019: Atox Bio announces exercise by BARDA of next option period to support continued development of reltecimod for NSTI

Apr 09, 2019: OSE Immunotherapeutics announces issuance of Canadian patent and notice of allowance of U.S. patent protecting CD28-Antagonist Immunotherapy FR104

Feb 19, 2019: Alpine Immune Sciences presents preclinical ALPN-101 GvHD data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)

Feb 14, 2019: Atox Bio announces appointment of Robert Greif as chief commercial officer

Feb 12, 2019: Alpine Immune treats first patient in Phase I trial of ALPN-101

Dec 03, 2018: Alpine Immune sciences showcases key preclinical data at 60th American Society of Hematology Annual Meeting and Exposition

Nov 29, 2018: Alpine Immune Sciences announces ALPN-101 data to be included in oral presentation at 60th American Society of Hematology Annual Meeting and Exposition

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Alpine Immune Sciences Inc, H2 2019

Pipeline by Atox Bio Ltd, H2 2019

Pipeline by Avacta Life Sciences Ltd, H2 2019

Pipeline by Bristol-Myers Squibb Co, H2 2019

Pipeline by Five Prime Therapeutics Inc, H2 2019

Pipeline by Imugene Ltd, H2 2019

Pipeline by OSE Immunotherapeutics, H2 2019

Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Pipeline by TheraMAB LLC, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports